North America Radiopharmaceutical CDMO Market

North America Radiopharmaceutical CDMO Market Size & Forecast:

• North America Radiopharmaceutical CDMO Market Size 2025: USD 1.68 Billion
• North America Radiopharmaceutical CDMO Market Size 2033: USD 3.65 Billion
• North America Radiopharmaceutical CDMO Market CAGR: 10.19%
• North America Radiopharmaceutical CDMO Market Segments: By Service Type (Process Development, API Manufacturing, Radiolabeling Services, Fill & Finish Services, Analytical Testing, Regulatory Support, Commercial Manufacturing, Others); By Radioisotope (Fluorine-18, Lutetium-177, Gallium-68, Actinium-225, Iodine-131, Technetium-99m, Copper-64, Others); By Application (Oncology, Cardiology, Neurology, Endocrinology, Infectious Diseases, Research Applications, Theranostics, Others); By End User (Pharmaceutical Companies, Biotechnology Companies, Academic Institutes, CROs, Nuclear Medicine Centers, Research Laboratories, Hospitals, Others); By Phase (Preclinical, Phase I, Phase II, Phase III, Commercial Manufacturing, Technology Transfer, Post-Approval Manufacturing, Others).

North America Radiopharmaceutical CDMO Market Summary

The North America Radiopharmaceutical CDMO Market was valued at USD 1.68 Billion in 2025. It is forecast to reach USD 3.65 Billion by 2033. That is a CAGR of 10.19% over the period.

The North America Radiopharmaceutical CDMO Market kind of lets pharmaceutical innovators hand off the hard development and manufacturing side of radioactive medicines used for cancer diagnosis, and also targeted therapy. These specialized partners bring the facilities, know-how in regulations , and very tightly controlled production spaces that are needed to deal with short lived isotopes ,and still get the product to healthcare providers on schedule. A few years back , the market was mostly about diagnostic imaging products, but now it’s leaning toward a wider set of therapeutic radiopharmaceuticals. That change means more manufacturing flexibility, plus more specialized isotope handling skills. The shift sped up once clinical outcomes for targeted radioligand therapies looked strong ,so investment followed and many development programs expanded. Meanwhile, isotope supply limits and logistics problems highlighted weak spots in older production networks, so manufacturers pushed to grow regional capacity. And since more drug developers choose outsourcing rather than building their own dedicated facilities, CDMOs are landing bigger, longer term contracts. All of that ties higher development activity to steady revenue growth .

Key Market Insights

• The North America Radiopharmaceutical CDMO Market is shifting away from diagnostic isotope production, and moving toward therapeutic radiopharmaceutical manufacturing, which is increasing the need for specialized CDMO capacity through 2030.
• The United States is still the main driver of regional revenue with roughly 85% market share in 2025, mainly backed by advanced nuclear medicine infrastructure and a lot of clinical trial momentum.
• Canada is showing the fastest regional growth over the forecast period, largely because of isotope production investments, along with public private research collaborations that keep scaling up.
• Commercial manufacturing services sit at nearly 48% market share, basically showing how pharmaceutical companies tend to outsource late-stage production rather than build their own dedicated facilities.
• Clinical development services remain the second largest segment, since radiopharmaceutical pipelines keep expanding, especially across oncology and precision medicine use cases.
• Therapeutic radiopharmaceutical manufacturing is expected to post the quickest growth through 2032 as targeted alpha and beta therapies steadily edge closer to commercialization.
• Oncology makes up more than 70% of the contract manufacturing demand, driven by rising clinical development in prostate, neuroendocrine, and metastatic cancer therapies.
• Precision oncology plus theranostic applications are the fastest growing clinical areas, because integrated diagnostic and therapeutic platforms are getting more regulatory pull and commercial acceptance.
• Pharmaceutical and biotechnology companies generate over 75% of outsourced manufacturing contracts, and at the same time emerging biotechnology firms are the fastest-growing customer group.

What are the Key Drivers, Restraints, and Opportunities in the North America Radiopharmaceutical CDMO Market?

The most powerful pull on the market is the fast commercialization of aimed radioligand therapies in oncology. Regulatory signoffs for fresh radiopharmaceutical treatments have nudged biotech companies and big pharma to broaden clinical pipelines while not really pouring hundreds of millions into dedicated radioactive manufacturing plants. By outsourcing, developers can tap into GMP compliant production, specialized isotope handling, plus regulatory know-how, all while lowering upfront capital spending and also speeding up development clocks. Because of this, there are now more multi-year manufacturing agreements, and CDMO income has grown beyond the old “just clinical supply” type contracts, you know?

Still, the biggest structural obstacle is the fairly narrow availability of medical isotopes and the specialized manufacturing infrastructure. The whole production chain leans on a handful of reactors, cyclotrons, and isotope providers. On top of that, manufacturing sites need wide regulatory approvals, radiation safety systems, and highly trained staff. These limits can not be fixed right away, so you get manufacturing bottlenecks, longer project schedules, and less ability to make emerging therapies at true commercial scale.

A big opportunity sits in growing domestic isotope production a nd building decentralized manufacturing networks across North America. If companies invest in Actinium-225, Lutetium-177, and next-generation alpha emitting isotopes, then pair that with automated manufacturing technologies and regional production facilities, logistics risks linked to short lived isotopes can get meaningfully reduced, even when timing is tight. Organizations that create an integrated development, manufacturing, and isotope supply platform will likely land in a strong position for durable collaborations, since precision oncology treatments keep moving forward through late-stage clinical development.

What Has the Impact of Artificial Intelligence Been on the North America Radiopharmaceutical CDMO Market?

Artificial intelligence and advanced digital technologies are, in a kinda indirect way, improving efficiency across radiopharmaceutical development and manufacturing. They do this by optimizing production planning, quality management, and how equipment performs. With AI-enabled scheduling systems, it becomes easier to coordinate isotope production with real manufacturing timelines, so short half-life materials waste is cut down more often. Also, automated image analysis plus machine learning models help with quality control by flagging production deviations sooner than conventional inspections. That ends up supporting batch consistency and regulatory compliance, in a way that feels more steady.

Then there’s predictive analytics, which is getting more and more useful for keeping an eye on cyclotrons, synthesis modules, cleanroom equipment, and other critical manufacturing assets. Machine learning algorithms can read sensor data and estimate maintenance needs before equipment failures interrupt the workflow. The result is higher operational uptime, with fewer unplanned stoppages. Digital twins, along with process simulation platforms, help fine tune manufacturing parameters too. They improve isotope utilization, lower production costs, and help technology transfer move faster between development teams and commercial facilities.

Even so, AI adoption still has constraints. Mainly it’s tied to high implementation costs, and limited access to standardized manufacturing datasets. Radiopharmaceutical production tends to run small batch volumes and uses very specialized process steps, which makes it hard to train strong predictive models across very different manufacturing environments. On top of that, many sites still rely on legacy equipment, so digital upgrades are often substantial, before more advanced AI solutions can deliver benefits consistently.

Key Market Trends

• Therapeutic radiopharmaceutical manufacturing has basically overtaken the diagnostic-focused expansion , once oncology drug pipelines started moving toward targeted alpha and beta emitter therapies after 2021.
• Drug developers now seem to prefer long-term CDMO partnerships instead of building their own radioactive manufacturing facilities, which cuts down capital needs , and it kind of speeds up commercialization too.
• Manufacturers also expanded domestic isotope production capabilities following the pandemic-era logistics disruptions, which made it pretty clear where the weak points were in cross-border supply chains , and that exposure was… noticeable.
• Automation technologies have become kind of routine in modern GMP facilities, helping production stay steadier, while also reducing operator exposure to radioactive materials.
• Pharmaceutical companies increasingly want an integrated CDMO partner that can handle development, manufacturing, packaging, and isotope logistics all under one agreement, not several scattered vendors .
• Since 2022, strategic collaborations among isotope producers, biotechnology companies, and healthcare providers have helped push next-generation theranostic platforms into the market faster.
• Investment shifted more strongly toward Actinium-225 and Lutetium-177 production, because clinical pipelines started prioritizing targeted radioligand therapies over conventional nuclear imaging products.
• The competitive edge now leans more on regional manufacturing expansion, dependable isotope sourcing, and regulatory know-how, rather than just raw production capacity alone.
• Digital manufacturing platforms and predictive maintenance technologies have improved facility utilization overall, while reducing those annoying production interruptions across specialized radiopharmaceutical operations , more than before.

North America Radiopharmaceutical CDMO Market Segmentation

By Service Type :

Service type segmentation kind of explains how contract development plus manufacturing efforts actually play into different stages of radiopharmaceutical production. Process development is mainly about building repeatable methods that make product performance more consistent, before the whole large scale production part kicks in. API manufacturing in turn supports producing the radioactive active ingredients , while radiolabeling services prepare the compounds with particular radioisotopes for medical use

Then you also have fill and finish services which handle sterile packaging, and that last preparation step before anything goes out for distribution. Analytical testing checks product quality, purity, and stability. Regulatory support helps with the paperwork and compliance obligations , and commercial manufacturing allows large scale production once the product gets approved. Other services can include specialized technical assistance depending on what the project really needs

By Radioisotope :

Radioisotope segmentation goes one step further, it points to the different radioactive materials used during manufacturing, for diagnostic plus therapeutic applications. Fluorine-18 and Gallium-68 are commonly chosen for diagnostic imaging because their short half lives help support accurate medical imaging, in a pretty practical way. Technetium-99m stays important too, especially for routine nuclear medicine examinations

For the treatment side, Lutetium-177, Actinium-225, and Iodine-131 support targeted therapy approaches, and that’s especially visible in cancer care. Copper-64 is used for both imaging and treatment purposes, which adds flexibility during product development. Other radioisotopes cover specialized clinical needs and research objectives, since new treatment options keep arriving in development

By Application :

Application segmentation kinda points to the medical conditions that are backed up by radiopharmaceutical development and manufacturing. In oncology, it is especially big because radioactive medicines help clinicians, identify tumors and also deliver targeted treatment, so it’s not only “find it”, but also “act on it”. Cardiology and neurology applications support physicians in judging heart performance and neurologic disorders through more advanced imaging methods.

Endocrinology, infectious diseases, and even research use cases keep growing, mainly because new radiopharmaceutical products are moving along the pipeline. Theranostics, combines diagnostic imaging with targeted therapy, and in practice it lets clinicians plan treatment based on what they see in each individual patient. There are also other applications, like extra clinical areas where radioactive medicines bring real medical value, not just theoretical use.

By End User :

End-user segmentation, is more about the orgs who rely on specialized manufacturing partners during product development, and later during commercialization. Pharmaceutical companies often outsource complicated manufacturing steps to boost efficiency and shorten development timelines. Biotechnology companies do the same, mostly because dedicated radioactive manufacturing facilities involve big investment and long building effort.

Academic institutes, contract research organizations, research laboratories, hospitals, and nuclear medicine centers contribute through research work, clinical studies, product testing, and actual patient care. Other end users include organizations taking part in specialized development programs that also need regulated manufacturing support, plus technical skills they might not have in house.

By Phase :

Phase segmentation kind of follows product development, starting from early lab studies to the point of commercial production, though it can feel like it overlaps a bit in practice. Preclinical activities tend to check product safety before any human studies really kick off. Then Phase I, Phase II, and Phase III build on each other with bigger and bigger levels of clinical evaluation, which ultimately generate both safety plus effectiveness information that regulators will want during review.

Once regulatory approval is in place, commercial manufacturing starts, and it mostly aims for steady product availability for healthcare providers. Technology transfer is what helps make sure manufacturing processes move between sites and still keep the same quality, or at least not noticeably change it. After approval, manufacturing keeps going to support ongoing production, while the other phases include more specialized tasks that are needed across the entire product lifecycle.

What are the Key Use Cases Driving the North America Radiopharmaceutical CDMO Market?

Radiopharmaceutical CDMO services are used, like, most heavily for oncology drug development and commercial manufacturing. Cancer treatments that run on radioisotopes need very specialized production, strict quality control, and quick distribution, since many isotopes have short half lives. Pharmaceutical and biotech companies end up leaning on CDMOs to satisfy these technical needs while speeding up product timelines and regulatory clearance too.

Adoption is also getting broader in neurology and cardiology programs, where radiopharmaceuticals help with advanced diagnostic imaging. Research labs, academic institutes, and contract research organizations are increasingly working side by side with CDMOs to manufacture materials for clinical trials , so new imaging agents can move through development without making a big investment in dedicated production sites.

Some newer use cases are showing up like theranostic medicines that blend diagnosis and treatment in one clinical plan, plus targeted alpha therapies that use next generation isotopes such as Actinium-225. With rising investment in precision medicine and personalized oncology, there should be more room for specialized manufacturing partners across the entire forecast period.

Which Regions are Driving the North America Radiopharmaceutical CDMO Market Growth?

The United States kind of represents the biggest regional market for radiopharmaceutical CDMO services across North America. There is strong regulatory oversight, a fairly mature pharmaceutical industry, and a wide nuclear medicine infrastructure that together help keep outsourcing activity steady, both for clinical as well as commercial manufacturing. You also have a broad set of research hospitals, biotechnology companies, academic institutions, and isotope production facilities, so product development can shift in a smooth way from laboratory work to commercial supply. And the ongoing investment in targeted radioligand therapies, plus the push for domestic isotope production, really keeps the long-term leadership role firmly in place.

Canada comes in next, as the second-largest contributor, but the growth pattern looks a little different than in the United States. Public research funding, ongoing collaboration between universities and healthcare organizations,and dependable isotope production capabilities make a solid base for manufacturing and clinical advancement. Canada also benefits from well-known expertise in nuclear science and medical imaging research, which lets domestic developers,and even international ones, tap into specialized manufacturing support. In the end this balanced ecosystem creates dependable project activity, rather than leaning mostly on huge commercial pharmaceutical investments.

Mexico is expected to see the quickest growth between 2026 and 2033. In recent years, the expansion of pharmaceutical manufacturing capabilities, plus rising clinical research activity, and stronger regulatory alignment with international quality standards— has basically opened fresh doors for contract manufacturing providers. At the same time, more capital going into healthcare infrastructure and a lot more cross border partnerships is pushing companies to take a hard look at Mexico as a supplementary production site for select development programs.

Who are the Key Players in the North America Radiopharmaceutical CDMO Market and How Do They Compete?

Competition in the North America Radiopharmaceutical CDMO Market is still fairly consolidated, though not completely, mainly because specialized manufacturing needs advanced set ups, real regulatory know-how, and safe access to medical isotopes. In practice, most firms go after differentiation through their technical capacity, regulatory discipline, manufacturing adaptability, plus consistent isotope delivery— not just pricing by itself. Even so, new players show up in a few selected spaces, but the high capex hurdles and strict quality requirements make fast growth difficult, so seasoned operators usually keep solid customer ties via longer term manufacturing agreements.

Curium kind of stands out with an integrated model that ties isotope production to radiopharmaceutical manufacturing, giving more control over ongoing supply continuity for commercial products. NorthStar Medical Radioisotopes lean on domestic isotope production and non-reactor approaches, which they say adds supply resilience while dialing back reliance on imported materials. Eckert & Ziegler, meanwhile , pushes growth by putting money into specialized radiopharmaceutical production facilities and advanced isotope processing methods, supporting both clinical efforts and commercial programs.

Jubilant Radiopharma seems to be growing its market reach by using a big radiopharmacy distribution system, which also ties in with their manufacturing services. In practice it helps product delivery run faster, more cleanly, and more consistent. Meanwhile Cardinal Health brings wide healthcare logistics know how into the mix along with nuclear pharmacy operations so it ends up feeling like one connected service. That integrated setup helps keep distribution dependable for time sensitive radiopharmaceutical products. Both firms keep pushing ahead, they add new facilities, upgrade technology, lean into strategic partnerships, and keep boosting manufacturing ability, all so they can match the shifting needs of precision oncology and targeted radioligand therapy developers.

Company List

• Curium Pharma
• Cardinal Health
• Eckert & Ziegler
• NorthStar Medical Radioisotopes
• Telix Pharmaceuticals
• Jubilant Radiopharma
• PharmaLogic
• Siemens Healthineers
• Novartis
• GE HealthCare
• Isotopia Molecular Imaging
• BWXT Medical
• Nusano
• ARTBIO
• Coquí RadioPharmaceuticals

Recent Development News

In April 2025, Curium announced acquisition of Nucleis. The acquisition added GMP radiopharmaceutical manufacturing and distribution capabilities, strengthening Curium’s PET radiopharmaceutical production network and expanding its CDMO-related manufacturing capacity in the nuclear medicine market.

Source: https://www.curiumpharma.com/

In June 2025, PharmaLogic Holdings Corp. completed the acquisition of a majority stake in Agilera Pharma AS. The transaction expanded PharmaLogic’s global radiopharmaceutical CDMO platform by adding development, manufacturing, and international distribution capabilities for therapeutic radiopharmaceuticals, enhancing scale and geographic reach.

Source: https://pharmalogicgroup.com/

What Strategic Insights Define the Future of the North America Radiopharmaceutical CDMO Market?

The North America Radiopharmaceutical CDMO Market is kind of structurally moving, toward very specialized integrated manufacturing ecosystems, where you see isotope production, GMP radiochemistry , analytical testing and even just in time distribution working like one whole operating model. This shift is being pulled forward by the expanding clinical pipeline of targeted radiopharmaceuticals and by this growing need for outsourced manufacturing know-how, that not many developers can actually build inside their own teams. 

There is also a less obvious risk, in the way critical radioisotope production and processing infrastructure becomes concentrated, so if there is a wobble in precursor isotope availability or transportation logistics, it can limit commercial scaling even when demand still looks strong. On the other hand, an opportunity is slowly forming around decentralized manufacturing networks, backed by automated synthesis platforms and digital quality systems, so regional production can sit nearer to treatment centers, while still keeping regulatory compliance intact. 

Market participants should focus on long term investments in isotope supply security, flexible manufacturing capacity, and strategic partnerships with nuclear infrastructure providers. That’s the best route to strengthen resilience and then capture more of the upcoming commercial opportunities.

North America Radiopharmaceutical CDMO Market Report Segmentation

By Service Type

• Process Development
• API Manufacturing
• Radiolabeling Services
• Fill & Finish Services
• Analytical Testing
• Regulatory Support
• Commercial Manufacturing

By Radioisotope

• Fluorine-18
• Lutetium-177
• Gallium-68
• Actinium-225
• Iodine-131
• Technetium-99m
• Copper-64

By Application

• Oncology
• Cardiology
• Neurology
• Endocrinology
• Infectious Diseases
• Research Applications
• Theranostics

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Academic Institutes
• CROs
• Nuclear Medicine Centers
• Research Laboratories
• Hospitals

By Phase

• Preclinical
• Phase I
• Phase II
• Phase III
• Commercial Manufacturing
• Technology Transfer
• Post-Approval Manufacturing